No Record Found
Sector
PharmaceuticalsOpen
₹17.9Prev. Close
₹17.56Turnover(Lac.)
₹14.5Day's High
₹18.43Day's Low
₹17.152 Week's High
₹22.7752 Week's Low
₹9.14Book Value
₹10.4Face Value
₹10Mkt Cap (₹ Cr.)
43.5P/E
0EPS
0Divi. Yield
0No Record Found
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 6.94 | 4.39 | 4.39 | 4.39 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -5.86 | -5.12 | -4.78 | -4.6 |
Net Worth | 1.08 | -0.73 | -0.39 | -0.21 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 0 | 0 | 0 | 1.8 |
yoy growth (%) | 0 | 0 | -100 | -76.3 |
Raw materials | 0 | 0 | 0 | -1.27 |
As % of sales | 0 | 0 | 0 | 70.86 |
Employee costs | -0.04 | 0 | -0.03 | -1.17 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | -0.18 | -0.05 | -0.16 | -1.41 |
Depreciation | -0.03 | -0.03 | -0.03 | -0.13 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.1 | 0 | -0.12 | -0.9 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | -100 | -76.3 |
Op profit growth | 198.36 | -63.66 | -86.72 | -334.74 |
EBIT growth | 207.45 | -63.16 | -86.27 | -477.56 |
Net profit growth | 202.1 | -63.82 | -93 | -1,909.97 |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,582.35 | 76.22 | 3,79,658.77 | 753.53 | 1.01 | 5,566.68 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,135.8 | 69.73 | 1,62,886.21 | 557 | 0.49 | 2,357 | 561.08 |
Cipla Ltd CIPLA | 1,577.65 | 24.67 | 1,27,435.32 | 1,303.13 | 1.01 | 4,501.66 | 397.38 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,596.4 | 61.23 | 1,21,713.05 | 551 | 0.17 | 2,567 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,566.1 | 58.53 | 1,05,917.96 | 412.76 | 0 | 2,541.36 | 354.69 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole Time Director & Chief Financial Officer
B V Anatha Kumar
Independent Director
Ananthkumar Shilpa
Executive Director
KUNIAMUTHUR NANJAPPAN ANAND
Company Sec. & Compli. Officer
Monika Sanwal
Independent Director
A Anitha
Managing Director
N Aravind
270 Shastri Market Indore,
Madhya Pradesh - 452007
Tel: -
Website: http://www.kabradrugs.com
Email: kabradrugs@gmail.com
Plot No. 60,
Electronic Complex, Pardeshipura,
Indore - 452010
Tel: 91-0731-3198601/3198
Website: www.ankitonline.org
Email: ankit_4321@yahoo.com
Summary
Kabra Drugs Ltd was incorporated as a Limited Company on August 22, 1989. The Company has set up a Unit at Indore for manufacturing of Ether derivatives which includes Diethyl Ether (Anesthesia), Solv...
Read More
Reports by Kabra Drugs Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.